当前位置: 首页 >> 检索结果
共有 7620 条符合本次的查询结果, 用时 5.4721633 秒

1. Letter by Skalidis et al Regarding Article, "Angiography-Derived Fractional Flow Reserve During Percutaneous Coronary Intervention".

作者: Ioannis Skalidis.;Stephane Cook.;Mario Togni.
来源: Circ Cardiovasc Interv. 2026年e016774页

2. Delivery System Support Prevents Endocardial Entanglement and Delamination During Left Bundle Branch Area Pacing.

作者: Yuichiro Miyazaki.;Hiroshi Nakajima.;Mark Rimmer.;Peter Hanna.;Justin H Hayase.;Duc H Do.;Kalyanam Shivkumar.;Shumpei Mori.
来源: Circ Arrhythm Electrophysiol. 2026年e014355页
The mechanisms behind endocardial entanglement and resultant delamination during left bundle branch area pacing, as well as potential solutions, have not been fully demonstrated in the human heart.

3. Heart Failure Guideline-Directed Medical Therapy Scoring Systems: A Scoping Review.

作者: Aaryan Dwivedi.;Zachary Cox.;Nathaniel M Hawkins.;Nima Moghaddam.;Margaret Sidsworth.;Sean Virani.;Douglas S Lee.;Ricky D Turgeon.
来源: Circ Heart Fail. 2026年e013881页
Guideline-directed medical therapy (GDMT) is central to the care of heart failure with reduced ejection fraction, yet no standard metric exists to quantify its implementation.

4. Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network.

作者: Olesya Plazyo.;Laura B Chopp.;Rishyanth Peela.;Kelly Young.;Haihan Zhang.;Rachael Bogle.;Ashley Hesson.;Elizabeth S Langen.;Ingrid L Bergin.;Li-Jyun Syu.;Jake Erba.;Joseph Kirma.;Poulami Dey.;Lin Zhang.;Mrinal K Sarkar.;William R Swindell.;Katherine A Gallagher.;Nicole L Ward.;Kanakadurga Singer.;J Michelle Kahlenberg.;Allison C Billi.;Andrzej A Dlugosz.;Santhi K Ganesh.;Lam C Tsoi.;Johann E Gudjonsson.
来源: Circulation. 2026年
Preeclampsia affects approximately 1 in 10 pregnancies, leading to severe complications and long-term health risks for both mother and offspring. While the etiology remains unclear, preeclampsia has been linked to both autoimmunity and the timing of menarche.

5. Transeptal Mitral Annuloplasty With the AMEND System: 6-Month Results of First in Man Cohort.

作者: Bruno Melica.;Shemy Carasso.;Adi Butnaru.;Irakli Gogorishvili.;Mikhael Metreveli.;Thomas Modine.;Levan Kurashvili.;Rivka Farkash.;David Meerkin.
来源: Circ Cardiovasc Interv. 2026年e015977页
The AMEND implant is a semi-rigid closed D-shaped annuloplasty ring deployed through a transvenous transeptal approach. It is aimed to affect selective anteroposterior dimensional reduction, improving leaflet coaptation, and reduce mitral regurgitation (MR). We report the 6-month outcomes of the first cohort treated.

6. Aortic-Left Ventricular Tunnel Secondary to LVOT Diverticulum in an Adult.

作者: Lan Lan.;Zhiling Liu.;Mei Zhu.;Hao Liang.;Qiao Li.;Jie Zhang.
来源: Circ Cardiovasc Imaging. 2026年e019659页

7. Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana.

作者: Fred Stephen Sarfo.;Albert Akpalu.;Ansumana S Bockarie.;Samuel Blay Nguah.;Nana Kwame Ayisi-Boateng.;Rexford Adu Gyamfi.;Agnes Amankwaah Arthur.;Christiana Duah.;Timothy Fiattor.;Kwadwo Gyebi Agyenim-Boateng.;Emmanuel Achab.;Tetteh Appiah Lambert.;Priscilla Abrafi Opare-Addo.;Sheila Adamu.;Manolo Agbenorku.;Nathaniel Adusei-Mensah.;Raelle Tagge.;Michael Ampofo.;Shadrack Osei Asibey.;Ruth Laryea.;Evans MacCready.;Victoria Aba Sam.;Kwaku Affrim Buadu.;Solomon Adu.;Nyantakyi Adu Darko.;Melvin Agbogbatey.;John H Amuasi.;Bruce Ovbiagele.
来源: Circulation. 2026年
Addressing the rising burden of stroke in low-income countries will require pragmatic and scalable interventions targeting major risk factors. Under routine care settings, <10% of adults living with hypertension ever achieve blood pressure control, accentuating risks for adverse vascular events. The effectiveness of mobile health-centered, nurse-led interventions for the control of hypertension among patients with recent stroke in a resource-limited African setting is unknown.

8. Hemodynamic and Clinical Outcomes of Transcatheter Valve Expansion in Degenerated Mitral Bioprostheses.

作者: Mark J Zorman.;Kaleb Foster.;Bas L Kietselaer.;Mayra E Guerrero.;Charanjit S Rihal.;Mackram F Eleid.
来源: Circ Cardiovasc Interv. 2026年e016270页
Transcatheter mitral valve-in-valve replacement is an established therapy for intermediate and high-risk patients with degenerated bioprostheses, but restricted transcatheter valve (THV) expansion within rigid surgical frames and elevated gradients have raised durability concerns. This study aimed to evaluate midterm outcomes of mitral valve-in-valve patients according to THV expansion and sizing strategy.

9. Sex-Specific Prognostic Value of Aortic Valve Calcium and the Risk for Aortic Stenosis: Multi-Ethnic Study of Atherosclerosis (MESA).

作者: Natalie Marrero.;Kunal Jha.;Jelani K Grant.;Alexander C Razavi.;Matthew J Budoff.;Sanjiv J Shah.;Jerome I Rotter.;Roger S Blumenthal.;Wendy S Post.;Martha Gulati.;Leslee J Shaw.;George Thanassoulis.;Michael J Blaha.;Seamus P Whelton.
来源: Circ Cardiovasc Imaging. 2026年e018849页
In general, females have lower aortic valve calcium (AVC) scores compared with males of similar age, and the AVC score threshold for diagnosing severe aortic stenosis (AS) is lower for females. We examined whether the association of AVC with the long-term risk of clinically significant AS differed for females compared with males.

10. Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.

作者: Nan Li.;Khadijeh Taherdangkoo.;Isabelle M Baatsch.;Tanya Guduru.;Qiuxing Meng.;Shilun Li.;Yanyi Zhou.;Xinwei Li.;Mengyu Zhu.;Sarah Polczer.;Claudia Geissler.;Eva Briem.;Remco T A Megens.;Heya Na.;Joerg Kumbrink.;Daniel Richter.;Ya Li.;Carolin Jethwa.;Alexander Bartelt.;Yvonne Döring.;Philipp von Hundelshausen.;Wolfgang Enard.;Christian Weber.;Maliheh Nazari-Jahantigh.;Andreas Schober.
来源: Circulation. 2026年
Hypercholesterolemia and a high-fat diet promote 2 macrophage subtypes involved in atherosclerosis by inducing lipid droplet accumulation in foamy macrophages (FMs) and inflammatory activation in non-foamy macrophages (NFMs). MicroRNAs are key regulators of macrophage function; for instance, miR-10a-5p reduces atherosclerosis and improves mitochondrial health in FMs, whereas miR-155-5p accelerates atherosclerosis by impairing efferocytosis. miR-147-3p is upregulated by inflammatory stimuli in macrophages and in atherosclerotic lesions, suggesting a role in NFMs.

11. Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.

作者: Isabela Landsteiner.;Lindsey K Stolze.;Tess E Peterson.;Andrew Perry.;Phillip Lin.;Quanhu Sheng.;Shilin Zhao.;Kaushik Amancherla.;Michael Y Mi.;Takenori Ikoma.;Laura P Cohen.;Ilya Giverts.;Joseph Campain.;Joao A C Lima.;Wendy S Post.;Kent D Taylor.;Robert Gerszten.;Stephen S Rich.;Russell Tracy.;Peter Durda.;Alexis C Wood.;Rajeev Malhotra.;Jerome I Rotter.;Clary Clish.;Matthew Nayor.;Eric R Gamazon.;Ravi V Shah.;Gregory D Lewis.
来源: Circulation. 2026年
Exercise unmasks limitations in multi-organ system reserve capacity characteristic of heart failure with preserved ejection fraction (HFpEF). However, the metabolic and genetic underpinnings of exercise deficits, and their cumulative contribution to HFpEF severity and prognosis, remain incompletely understood.

12. Compensating Heart Failure Cardiologists: Is the RVU Model the Right Model?

作者: Nir Uriel.;Boaz Elad.;Yevgeniy Brailovsky.;Kevin Clerkin.;Justin Fried.;Nikhil Narang.;Dor Lotan.;Ilan Richter.;Jayant Raikhelkar.;Adil Yunis.;Ersilia M DeFilippis.;Thomas M Cascino.;Snehal R Patel.;Shashank S Sinha.;Jennifer Haythe.;Marc E Richmond.;Manreet Kanwar.;Gabriel Sayer.;Ulrich P Jorde.
来源: Circ Heart Fail. 2026年e013838页
Physician compensation models in the United States are diverse, shaped by practice settings, specialties, and institutional factors. A notable shift in academic medical centers has been the transition from salary-based compensation to relative value unit (RVU)-based models. While this shift may align compensation with clinical productivity and facilitate budgetary planning, it has profound implications for physician satisfaction, burnout, and clinical practice, particularly in primarily cognitive/nonprocedural based specialties like advanced heart failure (AHF). This article explores the benefits and drawbacks of the RVU model, with a focus on its application in AHF care. The RVU system, designed to measure physician work, practice expenses, and malpractice risk, is associated with efficiency incentives but also risks prioritizing quantity over quality, especially in multidisciplinary fields like AHF. Patients with AHF often have multiple comorbidities requiring extensive management and care coordination across multiple subspecialties, outside of the work effort captured by a clinic visit. The RVU model may undervalue the comprehensive, longitudinal care AHF specialists provide. Through a detailed examination of inpatient and outpatient AHF management, we argue that the RVU model may inadequately capture the full scope of AHF care, which may contribute to systemic challenges, physician burnout, and a decline in interest in AHF subspecialty training. Hence, we call for a reconsideration of AHF physician compensation and productivity measurement that more accurately reflects the full breadth of comprehensive AHF care.

13. Letter by van IJzendoorn Regarding Article, "Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction".

作者: Marinus H van IJzendoorn.
来源: Circ Heart Fail. 2026年e014314页

14. Incidence, Timing and Clinical Significance of Immune-Mediated Myocardial Injury and Myocarditis After Gene Replacement Therapy: A Systematic Review and Meta-Analysis.

作者: Niccolò Maurizi.;Enrico Ammirati.;Elizabeth Silver.;Kimberly Hong.;Quan Bui.;Alessia Argirò.;Iacopo Olivotto.;Eric D Adler.
来源: Circ Heart Fail. 2026年e013771页
Although adeno-associated virus (AAV) gene-replacement therapy is a potentially transformative therapy for severe genetic diseases, its cardiac immunotoxicity may challenge broad clinical use.

15. Response by Ezekowitz to Letter Regarding Article, "Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction".

作者: Robert Margaryan.;Nariman Sepehrvand.;Wouter Ouwerkerk.;Jasper Tromp.;Ricky D Turgeon.;Justin A Ezekowitz.
来源: Circ Heart Fail. 2026年e014375页

16. Associations of the ICAM1 p.K56M HFpEF Risk Variant With Pericardial Adiposity and the Inflammatory Proteome.

作者: Anushree Aneja.;Kasen L Culler.;Jingzhong Ding.;Kent D Taylor.;Sanjiv J Shah.;Laura Rasmussen-Torvik.;Ravi B Patel.
来源: Circ Genom Precis Med. 2026年e005475页

17. Revascularization of Single-Vessel Coronary Artery Disease: Is it Still Worth Doing?

作者: Riccardo Liga.;Danilo Neglia.
来源: Circ Cardiovasc Imaging. 2026年e019753页

18. Cardiac Imaging in Clinical Trials of Intervention in Aortic Valve Stenosis.

作者: Bethlehem Mengesha.;Carlos Giuliani.;Georgios Tzimas.;Antonela Zanuttini.;Jonathon Leipsic.;Philippe Pibarot.
来源: Circ Cardiovasc Imaging. 2026年e018670页
Cardiac imaging and in particular transthoracic echocardiography and computed tomography play a major role in the selection of the patients for surgical or transcatheter aortic valve replacement, for the assessment or procedural success and early prosthetic valve hemodynamics following aortic valve replacement, and for the evaluation and follow-up of the prosthetic valve structure and function in the longer-term, which is key to demonstrate the valve durability. The purpose of this review article is thus to present the role of cardiac imaging, and particularly transthoracic echocardiography and computed tomography, in: (1) patient selection for intervention; (2) assessment of procedural and device success, and of intended performance of the valve; and (3) assessment of the long-term success, valve durability, and prognosis, for clinical trials of intervention in patients with aortic stenosis. Transthoracic echocardiography is the primary imaging modality to detect and stage bioprosthetic valve dysfunction. However, multimodality imaging, including transesophageal echocardiography and computed tomography, is often necessary to determine the cause of bioprosthetic valve dysfunction and make the differential diagnosis between prosthesis-patient mismatch, structural valve deterioration, thrombosis, pannus, or endocarditis. The clinical trials in the field of structural heart disease, and particularly in the field of aortic valve intervention, include imaging end points as part of the primary or key secondary end points. Standardized methods and definitions should be applied to adjudicate these imaging end points, and ideally, these trial end points should be analyzed by independent imaging core labs.

19. Gamut of Patients Referred to Cardiology for Question of Clonal Hematopoiesis.

作者: Ohad Oren.;Peter Libby.
来源: Circ Genom Precis Med. 2026年e005544页
Clonal hematopoiesis encompasses diverse somatic mutations in hematopoietic cells, ranging from age-related expansions to mutations acquired after cytotoxic therapy, with implications for hematologic malignancy and cardiovascular disease. We characterize the spectrum of patients referred to cardiology for clonal hematopoiesis, including incidental detection during cytopenia or cancer predisposition workup, coexisting malignancy, and posttherapy surveillance. High-risk features, large clone size, multiple mutations, and specific driver genes interact with traditional cardiovascular risk factors to influence ischemic events. Contextualizing clonal hematopoiesis by detection setting, genotype, and clinical history informs individualized cardiovascular evaluation and risk mitigation, guiding mechanistically targeted preventive strategies and trial design.

20. Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling.

作者: Anu Aggarwal.;Vara Prasad V N Josyula.;Nancy Wang.;Moua Yang.;Young Jun Shim.;Quinn P Kennedy.;Reina Samuel.;Naseer Sangwan.;Suman Guntupalli.;Matthew Godwin.;Huijun Edelyn Park.;Mariya Ali.;Courtney Jennings.;Bhairavi Rajasekar.;Alliefair Scalise.;Anthony Sloan.;Justin D Lathia.;Jessica Grondolsky.;Sarah M Schumacher.;Shaun Stauffer.;Keith R McCrae.;Thomas M McIntyre.;Scott J Cameron.
来源: Circulation. 2026年
Despite antiplatelet therapy, some patients remain at high ischemic risk because of drug nonresponsiveness or high residual platelet reactivity). We aimed to target an orphan platelet GPCR (G protein-coupled receptor) from the OR (olfactory receptor) family as a novel antithrombotic strategy.
共有 7620 条符合本次的查询结果, 用时 5.4721633 秒